Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Blood (2024) 144 (Supplement 1): 990.

https://doi.org/10.1182/blood-2024-200096

Published: 2024

Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Blood (2024) 144 (Supplement 1): 988.

https://doi.org/10.1182/blood-2024-194328

Published: 2024

Journal Articles

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Blood (2024) 144 (Supplement 1): 644.

https://doi.org/10.1182/blood-2024-201406

Published: 2024

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Ohad S Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Steven Horwitz

Blood (2024) 144 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2024-203577

Published: 2024

Journal Articles

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Blood (2024) 144 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2024-205544

Published: 2024

Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2023-174213

Published: 2023

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Blood (2023) 142 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2023-173677

Published: 2023

Journal Articles

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Monica Rondi, Silvia Ferrari, Anna Maria Barbui, Andrea Rossi, Chiara Pavoni, Anna Grassi, Federico Lussana, Alessandro Rambaldi, Giuseppe Gritti

Blood (2023) 142 (Supplement 1): 2331.

https://doi.org/10.1182/blood-2023-189911

Published: 2023

Journal Articles

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood (2023) 142 (Supplement 1): 302.

https://doi.org/10.1182/blood-2023-179304

Published: 2023

Journal Articles

Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy

Blood (2022) 140 (Supplement 1): 6504–6506.

https://doi.org/10.1182/blood-2022-166486

Published: 2022

Journal Articles

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2022) 140 (Supplement 1): 4568–4569.

https://doi.org/10.1182/blood-2022-165448

Published: 2022

Journal Articles

CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89 Zr-Crefmirlimab Berdoxam

Blood (2022) 140 (Supplement 1): 10733–10735.

https://doi.org/10.1182/blood-2022-158154

Published: 2022

Journal Articles

Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3818–3820.

https://doi.org/10.1182/blood-2022-156808

Published: 2022

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Marci Daugherty, Jonathan E Brammer, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 9387–9389.

https://doi.org/10.1182/blood-2022-169432

Published: 2022

Journal Articles

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 9461–9463.

https://doi.org/10.1182/blood-2022-157011

Published: 2022

Journal Articles

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Blood (2022) 140 (Supplement 1): 10339–10340.

https://doi.org/10.1182/blood-2022-166788

Published: 2022

Journal Articles

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Giuseppe Gritti, Federico Lussana, Silvia Ferrari, Anna Maria Barbui, Francesco Landi, Giulia Quaresmini, Gianmaria Borleri, Muriel Paganessi, Chiara Pavoni, Elisa Gotti, Chiara Capelli, Josee Golay, Martino Introna, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 10325–10326.

https://doi.org/10.1182/blood-2022-170120

Published: 2022

Journal Articles

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Blood (2022) 140 (Supplement 1): 3638–3641.

https://doi.org/10.1182/blood-2022-165977

Published: 2022

Journal Articles

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Blood (2022) 140 (1): 25–37.

https://doi.org/10.1182/blood.2021013648

Published: 2022

Includes: Supplemental data

Journal Articles

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Blood (2022) 139 (5): 732–747.

https://doi.org/10.1182/blood.2021012386

Published: 2022

Includes: Supplemental data

NARROW

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89 Zr-Crefmirlimab Berdoxam

Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only